12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Alnylam preclinical data

In a mouse model of AAT deficiency, single doses of IV ALN-AAT led to 90% knockdown of liver AAT mRNA and a >80% reduction in serum AAT at 48...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >